Skip to content
Screener

AbCellera Biologics Inc. ABCL Q2 2026 earnings

Reported August 5, 2026 · After market close

Revenue$4.1MMiss by $3.8M
EPS-$0.18Miss by $0.02
Revenue estimate$7.8M
EPS estimate-$0.16
“Since our last business update we signed two new collaborations, one with Jazz and one with Vertex, that leverage our T-cell engager platform to advance programs into the clinic and are adding over $100 million in upfront cash to our balance sheet.”
Carl Hansen

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$5.3M
EPS estimate-$0.18

Financials

Q2 2026

Income statement

See full
Revenue$4.1M-76.3%
Operating income-$62.8M-26.6%
Net income-$55.4M-59.6%
EPS (diluted)-$0.18-50.0%

Balance sheet

See full
Cash & equivalents$145.1M+23.5%
Total debt$135.6M-4.5%
Total equity$896.0M-11.0%
Total assets$1.3B-6.7%

Cash flow

See full
CapEx$2.1M-84.0%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$3.7B+177%
Enterprise value$3.69B+171%
P/S55.9×+15.3×

Profitability

See full
Operating margin-340.3%-127pp
Net margin-248.8%-83.6pp

Returns & leverage

See full
Return on equity-17.3%+2.1pp
Debt / equity0.2×0.0×
Current ratio12.8×+1.7×

Segments

By product

See full
Research fees$3.9M-41.2%
Licensing and royalty revenue$149.0K—

FAQ

When did AbCellera Biologics Inc. report Q2 2026 earnings?
AbCellera Biologics Inc. (ABCL) reported Q2 2026 earnings on August 5, 2026 after market close.
What were AbCellera Biologics Inc.'s Q2 2026 revenue and EPS?
AbCellera Biologics Inc. reported revenue of $4.1M and eps of $-0.18 for Q2 2026.
Did AbCellera Biologics Inc. beat estimates in Q2 2026?
Revenue missed the consensus estimate of $7.8M by $3.8M. EPS missed the consensus estimate of $-0.16 by $0.02.
How did AbCellera Biologics Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 76.3% from $17.1M a year earlier and eps declined 50.0% from $-0.12.
Where can I find AbCellera Biologics Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001703057-26-000044) and the 10-Q periodic report (0001703057-26-000046) directly on SEC EDGAR. The filing index links above go to sec.gov.